
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson's innovative medicine division reported revenues of $15.20 billion for the second quarter of 2025, exceeding consensus expectations, supported by strong growth in immunology and oncology. The company's management raised its fiscal year 2025 sales guidance to $93.2–$93.6 billion, driven by operational strength and favorable currency impacts, indicating a robust outlook for growth in the second half of the year and into 2026. Additionally, MedTech revenues reached $8.54 billion, surpassing expectations across all segments, underpinned by innovations and strategic pricing actions contributing to a resilient performance.
Bears say
Johnson & Johnson's financial outlook remains negative due to several fundamental challenges impacting its revenue growth across divisions. The company is facing significant risks from its pharmaceutical pipeline, with potential underperformance from newer product launches and an anticipated decline in sales from established drugs due to patent expirations, potentially resulting in total revenues falling below $57 billion by 2025. Additionally, competitive pressures in the MedTech segment and ongoing litigation costs may disrupt profitability, further complicating the company's growth trajectory in the coming years.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares